A phase III study of Alprostadil (Liprostin) for the treatment of peripheral artery disease (PAD)

Trial Profile

A phase III study of Alprostadil (Liprostin) for the treatment of peripheral artery disease (PAD)

Planning
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2018

At a glance

  • Drugs Alprostadil (Primary)
  • Indications Peripheral arterial disorders
  • Focus Therapeutic Use
  • Most Recent Events

    • 05 Feb 2018 According to an AngioSoma media release, the company is evaluating several contract research organizations ('CRO') for completion of our U.S. Food and Drug Administration ('FDA') protocol for Phase III.
    • 26 Jul 2016 New trial record
    • 14 Jul 2016 According to an AngioSoma media release, this phase III trial protocol has been approved by U.S. Food and Drug Administration.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top